|
Overview
Mission, Vision and Values
Management Team
Board of Directors
Scientific Advisory Board
Investors
Market Opportunity
|
 |
Quanterix will launch the first version of the break–through SiMoA detection platform by Q3 2013.
The first market targeted is the $1.5 billion protein life science immunodetection market.
Customers in clinical research and pharmaceutical laboratories need more sensitive, better performing,
automated and cost effective detection systems to advance the rapidly growing field of biomarker
development. There has not been a major break–through in the field of protein detection in almost
20 years. Quanterix is changing that. The SiMoA platform will enable new ways to conduct research
and detect the previously undetectable in a reliable, reproducible and cost–effective way helping to
realize the promise of personalized medicine. Following the research market launch, Quanterix will
enter the $25 billion in vitro diagnostics (IVD) market in 2014 focusing on existing high value IVD
assays that need substantial performance improvements and new biomarkers with novel clinically valuable
content. Many important IVD assays suffer from sensitivity limitations or are simply too complex and
therefore costly to operate in regular IVD labs. New biomarkers with game changing clinical value will
be added to the instrument menu as they move from the development stage into routine diagnostics.
Quanterix’ SiMoA represents a paradigm shift in the digital measurement of biomolecules in a format
that is simple, easy to use and cost effective thereby allowing thousands of laboratories to benefit from the system.
|
